WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Comprehensive review on Control Release Drug Delivery System

Akash Kumar[1], Lovepreet Kaur Sandhu[2], Sanjiv Duggal[3]

Global College of Pharmacy, Kahnpur Khui, Anandpur Sahib, Punjab, India, 140117
Corresponding Author: Lovepreet Kaur Sandhu
Email.id: sandhulovepreet1113@gmail.com.

ABSTRACT :

Controlled release drug delivery systems (CRDDS) have emerged as a transformative innovation in the field of pharmaceutical sciences, offering improved therapeutic efficacy, enhanced safety profiles, and better patient adherence. In contrast to traditional drug delivery approaches, which may lead to erratic plasma drug levels and necessitate frequent administration, CRDDS are specifically designed to dispense the active pharmaceutical ingredient (API) at a regulated pace, over a defined time span, and occasionally in a site-specific manner. This review presents an in-depth analysis of the core concepts, types, and release mechanisms associated with these systems. It also examines the use of both natural and synthetic polymeric carriers, while highlighting recent breakthroughs in areas such as nanotechnology and stimuli-responsive formulations. Additionally, the article discusses clinical applications currently in use and addresses the major obstacles that limit broader clinical implementation. By synthesizing current literature, this review aims to provide a solid foundation and forward-looking perspective on the role of CRDDS in advancing modern therapeutics.

Keywords:Controlled release, drug delivery, polymers, sustained release, targeted delivery, pharmacokinetics.

Introduction

Over the past few decades, drug delivery technologies have progressed significantly, with a growing focus on enhancing therapeutic efficiency and improving the overall patient experience. Within this context, **Controlled Release Drug Delivery Systems (CRDDS)** have emerged as a key advancement, offering the ability to administer drugs at a controlled rate—either systemically or at a specific site—over an extended duration. These systems are primarily designed to maintain drug levels within the desired therapeutic range, thereby reducing the potential for peaks and troughs commonly associated with conventional dosing methods.

Conventional drug administration techniques—such as oral tablets, injectables, and topical formulations—typically require frequent dosing schedules. This not only compromises patient adherence but also causes inconsistent drug concentrations in the bloodstream, which may result in sub-therapeutic effects or toxicity. CRDDS aim to overcome these challenges by enabling sustained, regulated, and targeted drug release, thus optimizing both pharmacokinetics and pharmacodynamics [1].

These systems are generally categorized according to their release mechanisms, which include diffusion-controlled, biodegradable, swelling-controlled, and osmotic-driven approaches. A wide range of materials, particularly polymers, are employed to modulate the drug release profile. Commonly utilized polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose, (poly lactic-co-glycolic acid) (PLGA), and chitosan offer advantages like biocompatibility and customizable release characteristics [2].

The field has further been revolutionized by recent developments in nanotechnology, smart biomaterials, and stimuli-responsive systems, which have allowed for greater precision in drug targeting, minimized dosing frequency, and improved bioavailability [3,4]. Examples include pH-sensitive and thermoresponsive carriers, which discharge the drug in response to specific physiological conditions, enhancing site-specific delivery and lowering the risk of systemic side effects [5].

Types of Controlled Release Drug Delivery Systems

Controlled Release Drug Delivery Systems (CRDDS) are systematically classified based on how they are engineered to manage the timing, rate, and site of drug release. This categorization is essential for tailoring drug delivery platforms to meet specific therapeutic objectives and selecting compatible materials. CRDDS can generally be divided into the following key types:

a.) Diffusion-Based Delivery Systems

These systems regulate drug release through a diffusion process across a polymer matrix or membrane. The drug may either be evenly dispersed within

the polymer (matrix type) or stored in a central core enclosed by a semi-permeable layer (reservoir type).

- **Matrix systems**: The drug is integrated into the polymer, and its release is dictated by the diffusion rate and gradual erosion of the matrix.
- **Reservoir systems**: The active compound is surrounded by a film or membrane that modulates its release.

Example: Sustained-release tablets made with ethyl cellulose [6].

b.) Dissolution-Controlled Delivery Systems

In this type, drug release is governed by the dissolution rate of either the drug itself or the carrier material. This is particularly useful for water-soluble drugs.

- **Coated (encapsulated) systems**: The drug is enclosed in a layer that dissolves slowly in bodily fluids.
- **Matrix dissolution systems**: The drug is distributed throughout a matrix that gradually dissolves.

Example: Enteric-coated pellets designed to release the drug in the intestinal tract using pH-sensitive polymers [7].

c.) Osmotic Pump Systems

These platforms operate on the principle of osmosis, where water from the gastrointestinal tract enters the system through a semipermeable membrane, dissolves the drug, and pushes it out via a pre-designed orifice.

- These systems provide controlled drug release largely independent of external factors like GI pH or motility.

Example: OROS® devices, such as Procardia XL [8].

d.) Systems Based on Swelling and Erosion

Such systems involve polymers that either absorb fluid and expand to form a gel barrier or degrade slowly, allowing the drug to diffuse out at a controlled pace.

- **Swelling-based systems**: Use hydrophilic materials such as hydroxypropyl methylcellulose (HPMC).
- **Erosion-based systems**: Employ biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA).

Example: Hydrogels formulated for targeted drug delivery to the colon [9].

e.) Ion-Exchange Resin Systems

Here, drugs are chemically bonded to resins and are released via ion exchange reactions in the gastrointestinal fluids. The drug ions are replaced by physiological counter-ions, enabling a gradual release.

Example: Sustained-release syrups using a chlorpheniramine-resin complex [10].

f.) Smart (Stimuli-Responsive) Delivery Systems

These are next-generation systems designed to release drugs in response to specific internal triggers such as pH changes, temperature variations, enzyme levels, or redox conditions.

- **pH-responsive systems**: Deliver the drug at specific sections of the GI tract based on pH.
- **Thermo-responsive systems**: Release the drug when local body temperature rises, such as during inflammation or fever.

Example: Nanogels that respond to pH levels for delivering anti-inflammatory agents to the colon [11].

Ideal Properties of Controlled Release Drug Delivery Systems (CRDDS)

A.) Consistent and Regulated Drug Release [12]

An effective CRDDS should deliver the active pharmaceutical ingredient (API) in a controlled and sustained fashion—ideally following a zero-order kinetics—to ensure that plasma drug levels remain stable and within the therapeutic range for a prolonged duration. This design eliminates the concentration spikes and troughs commonly observed in standard dosing approaches.

B.) Non-Toxicity and Biocompatibility [13,14]

All components involved in the formulation, including polymers and additives, must be biocompatible and free from toxicity. They should not trigger immune responses nor break down into harmful substances after administration. This is particularly critical for injectable or implantable drug delivery platforms.

C). Physicochemical and Chemical Stability [15]

The delivery system must safeguard the drug from degradation processes such as hydrolysis and oxidation during manufacturing, storage, and gastrointestinal transit. Both the drug and the carrier matrix should exhibit sufficient shelf-life and maintain structural and chemical integrity throughout.

D.) User-Friendly and Compliance-Enhancing Design [16]

To improve patient adherence, especially for long-term therapies, the system should allow for less frequent dosing and be easy to use. Preferred routes include oral and transdermal, which are non-invasive, though minimally invasive options like injectables may be used when necessary.

E.) Site-Specific (Targeted) Drug Delivery [17]

Advanced CRDDS should be capable of directing the therapeutic agent to specific tissues or organs—such as the colon, lungs, or tumor sites—to enhance efficacy while reducing systemic side effects. This requires integration of site-responsive polymers or ligand-based targeting mechanisms.

F.) Broad Drug Compatibility [18]

An ideal system should accommodate a diverse array of drugs, including hydrophilic and lipophilic compounds, peptides, and biologics. Flexibility in drug incorporation broadens the applicability of the delivery system.

G.) Scalable and Reproducible Manufacturing [19]

The delivery platform should be amenable to large-scale production while ensuring batch-to-batch uniformity in drug release behavior and content uniformity. This consistency is vital for regulatory approval and clinical application.

H.) Environmentally Degradable for Injectable/Implantable Systems [20,21]

In the case of implantable or injectable systems, the materials should biodegrade safely within the body, producing non-toxic byproducts that can be naturally excreted. This eliminates the need for surgical retrieval of the delivery device post-treatment.

Polymers in Controlled Release Drug Delivery Systems (CRDDS):

a.) Natural Polymers

These are derived from biological sources and are often biodegradable, biocompatible, and non-toxic, making them ideal for many pharmaceutical applications.

Example: A) Chitosan

Derived from crustacean shells (chitin).

Biodegradable, mucoadhesive, and enhances permeation across mucosal membranes.

Used in**:** Nasal, oral, and buccal delivery systems.[22]

B) Sodium Alginate [23]

Extracted from brown algae.

Forms hydrogels in presence of calcium ions – ideal for sustained release.

Used in: Gastroretentive and colon-specific delivery

C) Guar Gum & Xanthan Gum [24]

Plant-derived polysaccharides.

Swell in aqueous media and modulate drug release by matrix swelling or erosion.

Used in: Colon-targeted tablets.

b.) Synthetic Polymers in CRDDS

Synthetic polymers offer better control over drug release, higher stability, and modifiability. They can be tailored for different routes and rates of release.

Example: A) Hydroxypropyl Methylcellulose (HPMC)

Hydrophilic polymer that forms a gel upon hydration.

Used in: Oral sustained-release tablets.[25]

c.) Smart / Stimuli-Responsive Polymers

Example: A) Thermoresponsive Polymers (e.g., Poloxamers)

Undergo sol-gel transition near body temperature.

Used in**:** Injectable gels and ophthalmic delivery.[26]

B) Enzyme-Responsive Polymers

Break down in the presence of disease-related enzymes (e.g., cancerous tissue).

Used in: Tumor-targeted drug release.[27]

C) pH-sensitive Polymers (e.g., Eudragit S100, HPMC phthalate)

Release drug only at certain pH.

Used in**:** Colon and intestinal targeting.[28]

Polymer Type	Examples	Release Mechanism	Main Use
Natural	Chitosan, Alginate, Guar Gum	Swelling, gel formation	Mucoadhesive, colon targeting

Synthetic	HPMC, EC, PLGA, Eudragit	Diffusion, erosion, pH-triggered	Oral, injectable, enteric
Smart	Poloxamer, pH-sensitive, enzyme-sensitive	Triggered by pH/temp/enzymes	Tumor, colon, site-specific

❖ **Advantages of Controlled Release Drug Delivery Systems[29,30,31]**

- Improved Patient Compliance.
- Sustained and Consistent Drug Levels.
- Reduced Side Effects.
- Optimized Use of Drugs with Short Half-Lifes.
- Better Control of Site-Specific Delivery
- Improved Bioavailability.

❖ **Disadvantages of Controlled Release Drug Delivery Systems[33,34,35]**

- Complex Formulation Design
- High Cost of Development and Manufacturing
- Risk of Dose Dumping
- Limited Suitability for All Drugs
- Regulatory and Approval Challenges
- Difficulty in Removal Implants

❖ **Recent Advances in Controlled Release Drug Delivery Systems**

Over the past few years, Controlled Release Drug Delivery Systems have witnessed remarkable innovations, shifting the paradigm toward more accurate, patient-specific, and responsive drug delivery strategies. Cutting-edge advancements such as *nanotechnology***,** *stimuli-sensitive materials***,** and *3D fabrication technologies* have significantly enhanced the precision and efficiency of drug delivery platforms.

Among these, the deployment of *nanocarrier systems*—including *liposomes***,** *polymeric nanoparticles***,** *solid lipid nanoparticles (SLNs)***,** and *nanostructured lipid carriers (NLCs)*—has become particularly impactful. These nanoscale vehicles facilitate improved *drug solubility***,** *bioavailability***,** and *site-specific accumulation***,** owing to their ability to traverse biological membranes and concentrate within target tissues [36]. A prime example is *PEGylated liposomes* such as *Doxil®***,** which exhibit extended systemic circulation and diminished toxicity [37].

Additionally, the development of *stimuli-responsive ("smart") polymers* represents a pivotal breakthrough. These materials are engineered to respond to internal biological triggers like *pH***,** *temperature shifts***,** *enzyme activity***,** or *oxidative stress***,** enabling precisely timed and localized drug release. This is particularly valuable in managing diseases such as *cancer***,** *autoimmune disorders***,** and *metabolic conditions*. For example, *pH-responsive hydrogels* are utilized in *colon-targeted delivery*, remaining intact in the acidic stomach but releasing drugs upon reaching the more alkaline environment of the intestine [38].

Another frontier in CRDDS innovation includes *biodegradable implants* and *injectable hydrogel systems***,** which offer sustained drug delivery with minimal invasiveness. Polymers like *PLGA***,** *chitosan***,** and *polycaprolactone* are frequently employed for their ability to *biodegrade safely*, thereby negating the need for surgical retrieval [39].

Moreover, the application of *3D printing in pharmaceuticals* has enabled the construction of *tailor-made drug delivery systems***,** offering precise control over drug release patterns by manipulating dosage form architecture at a microstructural level . In tandem, *smart electronic systems*—commonly referred to as *"digital pills"*—integrate biosensors and microcontrollers to allow *real-time drug release monitoring* and *feedback-controlled administration* [40].

❖ **Mechanisms of Drug Release in CRDDS**

Controlled release drug delivery systems (CRDDS) are designed based on specific physicochemical mechanisms that regulate the release rate and improve drug bioavailability. Drug release typically occurs through one or more of the following processes: **diffusion, dissolution, degradation, osmosis, swelling**, and **ion exchange** [41].

a.) Diffusion-Controlled Systems [42]

In these systems, the release of the drug is governed by its diffusion through a polymer matrix or membrane. Two subtypes are commonly recognized:

Matrix Devices: The drug is uniformly distributed within a polymeric matrix. As the surrounding fluid penetrates the matrix, the drug dissolves and diffuses out gradually. The rate of release depends on drug concentration and matrix composition.

Reservoir Devices: These consist of a drug core surrounded by a rate-controlling membrane. The release occurs as the drug diffuses through this outer coating, offering more controlled and predictable kinetics.

b.) Dissolution-Controlled Systems [43]

These systems depend on the solubility of the drug or the polymer that encapsulates it. Drug release occurs as the outer layer of the dosage form dissolves in bodily fluids.

Encapsulated Dissolution Systems: The drug is enclosed in a coating that dissolves at a specific pH or time, enabling delayed or extended release.

Matrix Dissolution Systems: The drug is embedded in a water-soluble matrix that gradually dissolves, releasing the drug as it erodes.

c.) Erosion-controlled release [44,45]

It is based on the degradation of the polymeric matrix, either through enzymatic action or hydrolysis. This mechanism is widely applied in biodegradable systems, particularly those using polymers such as poly (lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), or chitosan, which degrade into non-toxic byproducts.

d.) Osmotic-Controlled Systems [46]

Osmotic systems use osmotic pressure as the driving force to release the drug. These devices typically have a semipermeable membrane that allows water to enter the system. The influx of water dissolves the drug, which is then released through a pre-formed orifice in a controlled manner. These systems are independent of pH and gastrointestinal motility, making them suitable for consistent release.

e.) Swelling-controlled mechanisms

It involve hydrophilic polymers that swell upon contact with bodily fluids, forming a gel barrier that regulates drug diffusion. This is common in hydrogel-based systems where release is controlled by polymer relaxation and diffusion dynamics

Ion exchange systems [47]

It releases drugs via reversible exchange reactions between the drug-bound resin and ions present in the gastrointestinal tract. This mechanism provides a predictable and pH-independent release rate, frequently used in liquid sustained-release formulations like cough syrups

Applications of Controlled Release Drug Delivery Systems (CRDDS) [48,49,50,51]

1. Chronic Disease Management

CRDDS are especially beneficial in treating chronic ailments like diabetes, epilepsy, and hypertension. These delivery platforms ensure consistent plasma drug concentrations over extended periods, thereby reducing the frequency of drug administration and significantly improving patient compliance and treatment outcomes.

2. Oncology (Cancer Treatment)

In oncology, CRDDS play a vital role by enabling the site-specific delivery of chemotherapeutic agents, thereby minimizing systemic exposure and

associated toxicities. Nanoscale carriers, such as PEGylated liposomes (e.g., Doxil®), enhance drug accumulation at tumor sites via the enhanced permeability and retention (EPR) effect, improving therapeutic selectivity and safety.

3. Gastrointestinal Disorders

CRDDS are tailored for site-specific drug release within the gastrointestinal tract, utilizing pH-sensitive or time-dependent polymers. This approach is particularly advantageous in managing conditions such as Crohn's disease and ulcerative colitis, where local drug release in the colon can yield targeted therapeutic action with fewer systemic side effects.

4. Hormonal Therapies

Controlled-release formulations are widely used in hormonal treatments, including contraceptives and hormone replacement therapy (HRT). Long-acting implants and injectables provide sustained hormone levels over weeks or months, improving therapeutic efficacy and user convenience while reducing the need for frequent dosing.

5. Central Nervous System (CNS) Disorders

For conditions affecting the central nervous system (CNS), such as Parkinson's disease, Alzheimer's, and schizophrenia, CRDDS offer controlled and prolonged drug delivery across the blood-brain barrier. This reduces dose-related side effects and helps maintain therapeutic levels over time, thus improving symptom control and patient stability.

6. Respiratory Treatments

Controlled release via inhalable formulations such as dry powder inhalers or liposomal aerosols is widely employed in treating asthma and chronic obstructive pulmonary disease (COPD). These systems provide sustained bronchodilation and reduce the need for repeated administration throughout the day.

Challenges of Controlled Release Drug Delivery Systems (CRDDS) [52,53,54,55]

1. Complexity in Formulation and Manufacturing Techniques

The development of controlled release systems necessitates a profound knowledge of how drugs interact with polymers, as well as the kinetics of drug release and system design parameters. Techniques such as microencapsulation, nanofabrication, and hot-melt extrusion, though effective, add significant complexity and elevate production costs due to their technical demands and precision requirements.

2. Elevated Costs in Development and Production

Controlled release formulations are often more expensive to develop than conventional dosage forms, primarily due to the high cost of specialized polymers, the need for advanced manufacturing infrastructure, and extended research and testing phases. These factors collectively pose economic challenges, particularly in the production of cost-sensitive or generic medications.

3. Regulatory Hurdles and Approval Delays

Due to their intricate design and use of novel materials, CRDDS face rigorous evaluation from regulatory authorities. Establishing the long-term safety, efficacy, and reproducibility of these systems often involves prolonged clinical studies and extensive documentation, making the approval process both time-consuming and costly.

4. Limited Suitability Across All Drug Types

Controlled release technology is not universally applicable to every drug compound. Drugs that possess a short half-life, require high doses, are unstable

under physiological conditions, or are absorbed only in specific regions of the gastrointestinal tract may not be ideal candidates for incorporation into CRDDS formulations.

5. Challenges in Achieving Constant (Zero-Order) Release

A major objective in CRDDS design is to maintain a steady drug release rate—ideally zero-order kinetics. However, achieving such a consistent release profile over extended durations is technically demanding, due to variable physiological conditions and polymer behavior over time.

Future Prospects of Controlled Release Drug Delivery Systems (CRDDS)

The advancement of Controlled Release Drug Delivery Systems (CRDDS) is being significantly influenced by the integration of innovative fields such as nanotechnology, biomaterials, artificial intelligence, and personalized healthcare. These developments aim to boost drug effectiveness, limit adverse effects, and enhance overall patient adherence to therapy.[56]

A major area of progress involves the application of nanotechnology, where delivery vehicles like nanoparticles, liposomes, dendrimers, and micelles are being specifically designed for precise and prolonged drug delivery. These nanoscale carriers are particularly valuable in treating cancers, neurological disorders, and infections by penetrating biological barriers and ensuring drug accumulation directly at the target site, thereby reducing toxicity to healthy tissues [57].

At the same time, there is a growing focus on stimuli-sensitive or smart drug delivery platforms that respond to internal triggers (such as enzymes, pH, or oxidative stress) or external stimuli (like temperature or ultrasound). These systems enable controlled, localized, and timely drug release, which is particularly beneficial in managing long-term illnesses like cancer and diabetes [58].

Additionally, the use of 3D printing and microengineering techniques is paving the way for the creation of individualized drug delivery systems. Such technologies make it possible to produce customized dosage forms with intricate release profiles and multi-drug combinations suited to each patient's specific therapeutic needs.[59]

Conclusion

Controlled Release Drug Delivery Systems (CRDDS) mark a significant evolution in pharmaceutical therapy by offering distinct advantages over traditional drug administration approaches. These systems are designed to provide prolonged, targeted, and consistent drug release, thereby enhancing therapeutic effectiveness, decreasing the frequency of dosing, minimizing adverse effects, and promoting better patient compliance—particularly in long-term or complex treatment regimens.

The field continues to advance with the incorporation of cutting-edge components such as biodegradable polymers, intelligent hydrogels, and nanoscale carriers, contributing to the development of more tailored and precise delivery methods. Breakthroughs in 3D printing, environment-responsive materials, and AI-driven customization are expanding the frontiers of what these systems can achieve.

However, the widespread application of CRDDS is still hindered by several challenges, including high production costs, regulatory complexities, scalability issues, and the need for long-term safety data. Nonetheless, with continued innovation and multidisciplinary collaboration, CRDDS are poised to significantly impact the future of drug delivery and personalized healthcare.

REFERENCES

1. Langer, R. (1990). *New methods of drug delivery*. Science, 249(4976), 1527–1533.
2. Dash, A. K., & Cudworth, G. C. (1998). *Therapeutic applications of implantable drug delivery systems*. Journal of Pharmacological and Toxicological Methods, 40(1), 1–12.
3. Siepmann, J., & Peppas, N. A. (2001). *Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)*. Advanced Drug Delivery Reviews, 48(2–3), 139–157.
4. Park, K. (2014). *Controlled drug delivery systems: Past forward and future back*. Journal of Controlled Release, 190, 3–8.
5. Qiu, Y., & Park, K. (2001). *Environment-sensitive hydrogels for drug delivery*. Advanced Drug Delivery Reviews, 53(3), 321–339.

6. Colombo, P., Bettini, R., & Peppas, N. A. (2004). *Drug release from swelling-controlled systems: Critical review*. Journal of Controlled Release, 94(2–3), 189–205.

7. Jantzen, G. M., & Robinson, J. R. (2002). *Sustained- and controlled-release drug delivery systems*. In Modern Pharmaceutics. CRC Press.

8. Theeuwes, F. (1975). *Elementary osmotic pump*. Journal of Pharmaceutical Sciences, 64(12), 1987–1991.

9. Peppas, N. A., & Langer, R. (1994). *Advances in biomaterials, drug delivery, and bio nanotechnology*. AIChE Journal, 40(2), 297–312.

10. Tiwari, S. B., Rajabi-Siahboomi, A. R., & Rajan, M. G. (2012). *Extended-release oral drug delivery technologies: monolithic matrix systems*. In Drug Delivery Systems.

11. Raza, A., Hayat, U., Rasheed, T., et al. (2019). *Stimuli responsive nanocarriers for targeted delivery of therapeutic agents: a review*. European Journal of Pharmaceutics and Biopharmaceutics, 142, 278–292.

12. Siepmann, J., & Peppas, N. A. (2001). *Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)*. Adv Drug Deliv Rev, 48(2-3), 139–157.

13. Langer, R. (1998). *Drug delivery and targeting*. Nature, 392(6679 Suppl), 5–10.

14. Anderson, J. M., & Shive, M. S. (1997). *Biodegradation and biocompatibility of PLA and PLGA microspheres*. Adv Drug Deliv Rev, 28(1), 5–24.

15. Rathbone, M. J., Hadgraft, J., & Roberts, M. S. (2003). *Modified-Release Drug Delivery Technology*. Marcel Dekker, Inc.

16. Hoffman, A. (2008). *Pharmacodynamic aspects of sustained release formulations*. Adv Drug Deliv Rev, 33(3), 185–199.

17. Chien, Y. W. (1992). *Novel drug delivery systems*. Marcel Dekker, Inc.

18. Qiu, Y., & Park, K. (2001). *Environment-sensitive hydrogels for drug delivery*. Adv Drug Deliv Rev, 53(3), 321–339.

19. Park, K. (2014). *Controlled drug delivery systems: Past forward and future back*. J Control Release, 190, 3–8.

20. Suri, S. S., Fenniri, H., & Singh, B. (2007). *Nanotechnology-based drug delivery systems*. J Occup Med Toxicol, 2(1), 16.

21. Zhang, H., & Burgess, D. J. (2012). *A programmable pulsatile release platform for hybrid oral drug delivery systems*. J Control Release, 162(1), 1–9.

22. Makadia, H. K., & Siegel, S. J. (2011). *Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier*. Polymers, 3(3), 1377–1397.

23. Singla AK, Chawla M. *Chitosan: A versatile biomaterial for drug delivery.* Int J Pharm. 2001; 243(1-2):19-31.

24. George M, Abraham TE. *Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review*. J Control Release. 2006;114(1):1-14.

25. Ford JL. *Design and evaluation of hydroxypropyl methylcellulose matrix tablets.* Drug Dev Ind Pharm. 1999;25(1):1–9.

26. Klouda L, Mikos AG. *Thermoresponsive hydrogels in biomedical applications.* Eur J Pharm Bio pharm. 2008;68(1):34–45.

27. Ramasamy T, et al. *Design and evaluation of enzyme-responsive nanocarriers for targeted drug delivery.* Drug Discover Today. 2014.

28. Sinha VR, Kumria R. *Polysaccharide matrices for microbial triggered drug delivery to the colon.* Drug Dev Ind Pharm. 2004;30(2):143-50.

29. Robinson JR, Lee HL. *Controlled Drug Delivery: Fundamentals and Applications*, 2nd ed., Marcel Dekker, 1987.

30. Siepmann J, Peppas NA. *Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC).* Adv Drug Deliv Rev. 2001;48(2-3):139–157.

31. Brahmankar DM, Jaiswal SB. *Biopharmaceutics and Pharmacokinetics – A Treatise*, 2nd ed., Vallabh Prakashan, 2009.

32. Park K. *Controlled Drug Delivery Systems: Past Forward and Future Back.* J Control Release. 2014;190 :3-8.

33. Hoffman AS. *The origins and evolution of "controlled" drug delivery systems.* J Control Release. 2008;132(3):153–163.

34. Colombo P, Bettini R. *Drug release modulation by physical restrictions of matrix swelling.* J Control Release. 2003;90(1):97-109.

35. Danaei M, et al. *Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems.* Pharmaceutics. 2018;10(2):57.

36. Barinholtz Y. *Doxil® — the first FDA-approved nano-drug: lessons learned.* J Control Release. 2012;160(2):117–134.

37. Mura S, Nicolas J, Couvreur P. *Stimuli-responsive nanocarriers for drug delivery.* Nat Mater. 2013;12(11):991–1003.

38. Okada H. *One- and three-month release injectable microspheres of the LH-RH super agonist leuprolide acetate.* Adv Drug Deliv Rev. 1997;28(1):43–70.

39. Goyanes A, et al. *3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics.* Mol Pharm. 2015;12(11):4077–4084.

40. Kalantar-Zadeh K, et al. *A wearable sensing and feedback system for monitoring gastrointestinal activity.* Nat Electron. 2018; 1:79–87.

41. Langer R, Peppas NA. *Advances in biomaterials, drug delivery, and bio nanotechnology.* AIChE Journal. 2003;49(12):2990–3006.

42. Siepmann J, Peppas NA. *Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC).* Adv Drug Deliv Rev. 2001;48(2–3):139–157.

43. Colombo P, et al. *Drug release modulation by physical restrictions of matrix swelling.* J Control Release. 1999;61(1–2):83–91.

44. Anderson JM, Shive MS. *Biodegradation and biocompatibility of PLA and PLGA microspheres.* Adv Drug Deliv Rev. 1997;28(1):5–24.

45. Dash TK, Konkimalla VB. *Poly-ε-caprolactone based formulations for drug delivery and tissue engineering: A review.* J Control Release. 2012;158(1):15–33.

46. Peppas NA, Bures P, Leobandung W, Ichikawa H. *Hydrogels in pharmaceutical formulations.* Eur J Pharm Bio pharm. 2000;50(1):27–46.

47. Hoffman AS. "The origins and evolution of 'controlled' drug delivery systems." *J Control Release*. 2008;132(3):153-163.

48. Chourasia MK, Jain SK. "Pharmaceutical approaches to colon targeted drug delivery systems." *J Pharm Pharm Sci*. 2003;6(1):33-66.

49. Allen TM, Cullis PR. "Drug delivery systems: entering the mainstream." *Science*. 2004;303(5665):1818-1822.

50. Patel T, et al. "Nanoparticulate drug delivery systems for CNS therapy." *J Control Release*. 2009;130(2):98-104.

51. Park K. "Controlled drug delivery systems: past forward and future back." *J Control Release*. 2014; 190:3-8.

52. Siepmann J, Peppas NA. "Modelling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)." *Adv Drug Deliv Rev*. 2012; 64:163–174.
53. U.S. FDA Guidance for Industry. "Extended-Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations." 1997.
54. Brahmankar DM, Jaiswal SB. *Biopharmaceutics and Pharmacokinetics*. Vallabh Prakashan; 2015.
55. Tiwari G et al. "Drug delivery systems: An updated review." *Int J Pharm Investing*. 2012;2(1):2–11.
56. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. *Adv Drug Deliv Rev*. 2013;65(1):36–48.
57. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: Therapeutic applications and developments. *Clin Pharmacol Ther*. 2008;83(5):761–769.
58. Goyanes A, et al. 3D printing of medicines: Engineering novel oral devices. *Drug Discover Today*. 2015;20(12):1393–1399.
59. Khaled SA, Burley JC, Alexander MR, et al. 3D printing of five-in-one dose combinations. *Int J Pharm.* 2015;494(2):643–650.